Anixa Biosciences Inc (ANIX): Operating Cash Flow
-$7.17M
Year ended 2025-10-31
-$7.38M
Trailing 12 months to 2026-07-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | -$7.17M | n/m | 2026-01-12, From 2024-11-01 |
| 2024-10-31 | -$7.33M | n/m | 2026-01-12, From 2023-11-01 |
| 2023-10-31 | -$6.21M | n/m | 2025-01-10, From 2022-11-01 |
| 2022-10-31 | -$6.49M | n/m | 2024-01-16, From 2021-11-01 |
| 2021-10-31 | -$4.94M | n/m | 2023-01-04, From 2020-11-01 |
| 2020-10-31 | -$6.18M | n/m | 2022-01-04, From 2019-11-01 |
| 2019-10-31 | -$4.74M | n/m | 2021-01-07, From 2018-11-01 |
| 2018-10-31 | -$4.27M | n/m | 2020-01-09, From 2017-11-01 |
| 2017-10-31 | -$3.80M | n/m | 2019-01-11, From 2016-11-01 |
| 2016-10-31 | -$3.38M | n/m | 2018-01-09, From 2015-11-01 |
| 2015-10-31 | $1.36M | n/m | 2016-12-08, From 2014-11-01 |
| 2014-10-31 | -$2.38M | n/m | 2015-12-23, From 2013-11-01 |
| 2013-10-31 | -$3.19M | n/m | 2015-01-29, From 2012-11-01 |
| 2012-10-31 | -$3.14M | n/m | 2014-01-17, From 2011-11-01 |
| 2011-10-31 | -$716.0K | n/m | 2013-01-29, From 2010-11-01 |
| 2010-10-31 | -$2.41M | n/a | 2012-01-30, From 2009-11-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | -$7.17M | n/m |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | -$12.89M | n/m |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | -$24.59M | n/m |
| Aditxt, Inc. (ADTX) | 2025-12-31 | -$25.69M | n/m |
| Synlogic, Inc. (SYBX) | 2025-12-31 | -$4.36M | n/m |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | -$26.82M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$9.76M | n/m |
| Cingulate Inc. (CING) | 2025-12-31 | -$17.25M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$23.12M | n/m |
Compare ANIX, APRE, RVPH, ADTX side by side · Screen every company in Pharmaceutical Preparations ↗